Cure CMT
Cure CMT
Cure CMT, a patient-driven venture philanthropy organization dedicated to accelerating treatments for Charcot–Marie–Tooth (CMT) disease, today announced a strategic investment in EverTree Bio to support the advancement of the company’s therapeutic program for Charcot–Marie–Tooth disease type 1A (CMT1A). The investment reflects Cure CMT’s mission to catalyze high-impact, translational programs that can meaningfully improve outcomes for patients and families. The investment was evaluated through Cure CMT’s CURES Team, the organization’s scientific and diligence committee. The review included scientific rationale, development feasibility, and alignment with Cure CMT’s patient-centered priorities for speed, rigor, oversight and patient impact.
“Cure CMT exists to move promising science into real-world therapies but faster,” said Patrick Livney, CEO of Cure CMT. “EverTree Bio’s CMT1A small molecule program aligns with our commitment to back strong scientific and management teams pursuing credible, disease-relevant strategies. This investment is about momentum: advancing a safe and efficacious program that we believe can make a tangible difference for the CMT community in the near future.”
Sarah Kishinevsky, PhD, CEO of EverTree Bio, emphasized the importance of mission-aligned capital in rare disease development. “CMT1A remains a profoundly underserved disease, and advancing a program from concept toward the clinic takes both scientific excellence and the right partners,” said Kishinevsky. “Cure CMT brings more than capital, and they bring purpose, diligence, and deep experience and engagement with the patient community. We’re excited to work together to accelerate our CMT1A program and expand what’s possible for patients through this investment by Cure CMT.”
“Cure CMT’s CURES Team conducted a rigorous, pragmatic evaluation focused on what it will take to advance the program efficiently and de-risk the next development steps for their CMT1A small molecule program,” said Paul August, PhD, Cure CMT board member and head of the CURES Team. “Our goal is to support programs with a sound mechanistic foundation and a credible path to meaningful clinical translation. EverTree Bio demonstrated a thoughtful strategy and strong execution, and we’re pleased to help propel their CMT1A efforts forward.”
About Cure CMT [Eatonton, Georgia]
Cure CMT is a patient-driven venture philanthropy organization committed to accelerating the development of therapies for Charcot–Marie–Tooth disease. CureCMT partners with researchers, biotech companies, and strategic stakeholders to advance promising programs through targeted investments, scientific diligence, and patient-centered collaboration.
About EverTree Bio: [San Francisco, California]
EverTree Bio is a drug discovery company developing transformative therapies for Charcot–Marie–Tooth disease and other neurological disorders. The company’s integrated platform combines proprietary stem cell technology with advanced artificial intelligence to drive a robust pipeline targeting the underlying biology of disease, with the goal of delivering meaningful, disease-modifying treatments for patients.
Media Contact
CureCMT: Patrick Livney, CEO
pal@cure-cmt.org
847.609.8525
EverTree Bio: Sarah Kishinevsky, PhD, CEO
sarah@evertreebio.com